Consensus $16.30. Lowers FY25 revenue view to up 7.4%-8% from up 7.5%-8.6%. Raises FY25 free cash flow view to $1.17B-$1.29B from $1.13B-$1.28B. The company said, “Labcorp (LH) is updating 2025 full year guidance to reflect its third quarter performance and full year outlook. The following guidance assumes foreign exchange rates effective as of September 30, 2025, for the remainder of the year. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases and dividends.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH:
- Labcorp reports Q3 adjusted EPS $4.18, consensus $4.14
- Labcorp’s Role in Pioneering Non-Invasive Preeclampsia Screening: A Market Perspective
- Notable companies reporting before tomorrow’s open
- LH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Labcorp to offer Elecsys pTau181 test for Alzheimer’s disease